News

Science Daily19h
Beyond Ozempic: New weight loss drug rivals surgery
Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that ...
Le Lézard12h
Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
Incyte today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in ...